Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback